401P Translation of the IDEA trial into clinical practice: Evaluation of implementation of a new guideline

Abstract

The pivotal IDEA trial showed marginal differences in survival outcomes for 3 vs 6 months of adjuvant chemotherapy (ACT) in stage II and III colon cancer (CC). Severe treatment toxicity was substantially lower in the short treatment regimen. Therefore, in 2017 the Dutch colorectal cancer (CRC) guideline was revised and currently recommends 3 months of oxaliplatin (OX)-based ACT. In addition, the definition of high-risk stage II CC was restricted to include only pathological T4 (pT4) tumors (instead of presence of poor differentiation, lymph node harvest <10, lymphovascular invasion and perforation/obstruction at presentation).